{"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants experienced events","groupId":"OG000","lowerLimit":"8.87","upperLimit":"NA","value":"48.20"},{"comment":"Insufficient number of participants with events","groupId":"OG001","lowerLimit":"4.70","upperLimit":"NA","value":"20.80"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"226"},{"groupId":"OG001","value":"226"}],"units":"Participants"}],"description":"The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.","dispersionType":"Inter-Quartile Range","groups":[{"description":"brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone brentuximab vedotin: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG000","title":"A+CHP"},{"description":"cyclophosphamide, doxorubicin, vincristine, and prednisone doxorubicin: 50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles prednisone: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles vincristine: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles cyclophosphamide: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles","id":"OG001","title":"CHOP"}],"paramType":"MEDIAN","populationDescription":"The Intent-to-Treat (ITT) Analysis Set includes all randomized patients. Patients are included in the treatment group assigned at randomization regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 60 months","title":"Progression-free Survival Per Independent Review Facility (IRF)","type":"PRIMARY","unitOfMeasure":"months"}